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Abstract
Introduction—Primary progressive aphasia (PPA) displays variable progression trajectories that
require further elucidation.
Methods—Longitudinal quantitation of atrophy and language over 12 months was completed for
PPA patients with and without positive amyloid PET (PPAAβ+ and PPAAβ−), an imaging
biomarker of underlying Alzheimer’s disease.
Results—Over 12 months, both PPA groups showed significantly greater cortical atrophy rates in
the left versus right hemisphere, with a more widespread pattern in PPAAβ+. The PPAAβ− group
also showed greater decline in performance on most language tasks. There was no obligatory
relationship between the logopenic PPA variant and amyloid status. Effect sizes from quantitative
MRI data were more robust than neuropsychological metrics.

Author Manuscript

Discussion—Preferential language network neurodegeneration is present in PPA irrespective of
amyloid status. Clinical and anatomical progression appears to differ for PPA due to Alzheimer’s
disease versus non–Alzheimer’s disease neuropathology, a distinction that may help to inform
prognosis and the design of intervention trials.
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1.

Introduction
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Primary progressive aphasia (PPA) is a clinical dementia syndrome defined by deterioration
of language functions over time and initial relative sparing of other cognitive domains [1]. It
is associated with two main classes of neuropathology: frontotemporal lobar degeneration
(FTLD) and Alzheimer’s disease (AD). In vivo biomarkers such as amyloid positron
emission tomography (PET) are emerging and hold promise for determining contributing
underlying neuropathology during life. Thus far, amyloid PET biomarker studies in PPA
have shown good reliability for detection of underlying pathology and reinforced the notion
that relationships between clinical subtypes (agrammatic [PPA-G], semantic [PPA-S], and
logo-penic [PPA-L] [2,3]) and underlying neuropathology are probabilistic rather than
deterministic [4–7].
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Determinants of the pace of decline in PPA are incompletely understood, especially whether
the presence of AD versus non-AD pathology influences the rate of deterioration. This is in
part because of a dearth of prospective longitudinal investigations [8–14] relative to crosssectional investigations and the historic lack of in vivo neuropathologic biomarkers. Disease
duration estimates for individuals with PPA range from 3 to 20 years, highlighting the
individual variability in progression rates. Some data suggest that those with FTLD
neuropathology may progress more rapidly than those with AD neuropathology [9], but
these data are relatively sparse.
This prospectively designed study assessed whether cortical and neuropsychological change
could be detected at 6-month intervals in non–semantic PPA participants with and without
elevated amyloid PET. Of particular interest was determining whether atrophy rates differed
for PPA patients with suspected AD versus non-AD neuropathologic change and whether
progressive atrophy remained left lateralized over time. It expands the existing literature by
offering a prospective design, examining clinical and imaging decline at relatively short 6month intervals, and stratifying by suspected underlying pathology with robust imaging
biomarkers. Understanding the biological factors influencing the rate of decline is essential
for uncovering mechanisms underlying clinical expression, designing intervention targets
and outcomes, and developing care plans for individuals living with PPA.

Author Manuscript

2.
2.1.

Methods
Participants
Participants were recruited from 2012 to 2016 into Northwestern University’s PPA Research
Program for a prospective study examining disease progression at 6-month intervals. The
Northwestern University Institutional Review Board approved this study, and written
informed consent was obtained from each participant.
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Participants were required to be right-handed and meet root PPA diagnostic criteria, namely,
an initially isolated and progressive language impairment due to neurodegenerative disease
[15–17]. The clinical diagnosis was confirmed for each participant by a behavioral
neurologist (M.M.M.). Clinical subtypes were assigned according to previously established
research guidelines [16]. Participants presenting with single-word retrieval and repetition
impairments along with relative sparing of word comprehension were classified as PPA-L.
Participants presenting with a salient grammatical impairment, effortful speech, and relative
preservation of word comprehension were classified as PPA-G. Participants with mild-tomoderate non–semantic PPA (i.e., PPA-G or PPA-L variants), with a Western Aphasia
Battery [18] Aphasia Quotient (WAB-AQ) score of ≥65 at their initial visit were included.
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Participants were required to have amyloid PET imaging with 18F-florbetapir at a single
time point to determine biomarker status and longitudinal MR and neuropsychological
testing at 6-month intervals over the course of 12 months. All PPA participants completed
three MR imaging visits (initial, 6-months, and 12 months).
Twenty-five community dwelling cognitively healthy controls of similar age and education
level with MR imaging at a single time point were used as a comparison group for some of
the MRI analyses (Table 1).
2.2.

Neuropsychological measures

Author Manuscript

2.2.1. Language domains—The WAB-AQ [18] measured aphasia severity based on
auditory comprehension, naming, repetition, and spontaneous speech. Grammatical
processing was measured using 15 noncanonical sentence items from the Northwestern
Anagram Test [19]. Moderately difficult items from the fourth edition of the Peabody
Picture Vocabulary Test [20] were used as a measure of lexical-semantic processing. Naming
ability was assessed with the Boston Naming Test [21]. Repetition was quantified using the
six most difficult items from the WAB-Repetition Subtest [22].
2.2.2. Non-language domains—Initial presence of deficits in memory, comportment,
and/ or visuospatial abilities precludes a PPA diagnosis but can emerge over time. These
domains were deemed to be intact at the initial visit by formal test scores, informant report,
and/or clinician assessment by an expert behavioral neurologist (M.M.M). Presence of
motor-speech impairments was assessed based on clinical impression and/or apraxia of
speech measures. Global measures of functioning included the activities of daily living
questionnaire and Clinical Dementia Rating Scale [23–25].
2.3.

Imaging acquisition
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T1-weighted 3D MP-RAGE sequences (TR = 2300 ms, TE = 2.91 ms, TI = 900 ms, flip
angle = 9°, FoV = 256 mm), recording 176 slices at a slice thickness of 1.0 mm, were
acquired on a 3T Siemens TIM Trio using a 12-channel birdcage head coil.
PET imaging for the PPA group was performed on a Siemens Biograph 40 TruePoint/TrueV
PET-CT system. A computed tomography scan was acquired for attenuation correction
followed by a 20-min dynamic PET acquisition 50 minutes after administration of 370 MBq
18F-florbetapir.
Alzheimers Dement. Author manuscript; available in PMC 2020 April 01.
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A board-certified nuclear medicine physician (author, A.K.A.) completed a visual read of
each florbetapir PET scan to determine if uptake was elevated (Aβ+) or not (Aβ−) [26].
Briefly, individuals were considered Aβ+ if there was increased retention of the tracer in the
cortical gray matter, defined as either loss of gray-white contrast in at least two cortical
regions or, as intense, focal uptake in at least one cortical region. The PET scan was
considered Aβ− when there was preserved gray/white contrast throughout the cortex or loss
of gray/contrast was isolated to one region only. This method showed strong test-retest
reliability [27], and in an autopsy study, the visual reads were slightly more reliable than the
quantitative reads [26]. Visual reads are also important because previous reports [28,29]
suggest PPAAβ+ individuals can show focal, asymmetric uptake (left > right), which may not
be detected by the standard volumes of interest developed and tested in dementia of the
Alzheimer’s type due to AD [27].
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2.5.

Cortical thickness and volume measurements
MR images were processed using the cross-sectional [30] and longitudinal [31] pipelines
from FreeSurfer (v5.1.0). Topological surface errors were corrected by manual intervention
according to established guidelines [32] in an iterative fashion until completely resolved.
Cortical thickness estimates were calculated by measuring surface distances between
representations of the white-gray and pial– cerebrospinal fluid boundaries.
Whole-brain vertex-wise cortical thickness analyses were used to identify differences
between groups at single time points and within each group across time points. Vertex-wise
Cohen’s d cortical thickness effect-size maps were generated to supplement the significance
comparisons.
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In addition to whole-brain vertex-wise cortical thickness analysis, two bilateral a priori
regions of interest (ROIs) described in our previous longitudinal study [13] were used: (1) a
cortex ROI of the entire neocortical surface, which served as a global measure of atrophy for
each hemisphere [33], and (2) a revised language network ROI defined for the perisylvian
cortex (PSTCR), which was identical to the previously described [13] PSTC ROI except that
the insula was excluded in the revised version to provide a focal cortical language network
ROI.
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Estimates of cortical gray matter volume were extracted from the subject native space for the
two bilateral ROIs. The volumetric estimates (ROInative) were adjusted for head size using
the estimated total intracranial volume (eTIVnative) calculated from the unbiased withinsubject template [34]. Normalized volume (ROInormalized) at each visit was calculated as
follows:
ROInormalized = ROInative /eTIVnative × eTIVfsaverage,

where fsaverage is FreeSurfer’s MNI-space brain template (eTIVfsaverage = 1,948,106 mm3).
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Volume loss was calculated as the percent change in volume over 6- and 12-month intervals
as follows:
Percentchange = Visit−AROInormalized − Visit
−BROInomalized /Visit − AROInomalized × 100

Visit A is chronologically earlier.
2.6.

Statistical analysis
Measures included demographics, clinical information, cortical thickness, ROI volume, and
neuropsychological tests. PPAAβ+, PPAAβ−, and control data were compared using analysis
of variance, t-tests, or Fisher’s exact tests.

Author Manuscript

Vertex-wise cortical thickness between-group differences were calculated by conducting a
general linear model across every vertex along the cortical surface, derived from structural
MR data processed with FreeSurfer. Within-group longitudinal vertex-wise analyses were
conducted using paired t-tests along the cortical surface using a false discovery rate of 0.05
[35].
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Volume was analyzed using a mixed linear model with percent change as the dependent
variable and amyloid status, hemisphere, and their interaction as covariates. This model
accounted for repeated measures (left hemisphere [LH] and right hemisphere [RH] of the
same person) and an unstructured covariance pattern. Two post hoc t-tests were used to
compare hemispheres by amyloid status and two tests compared rates of change (PPAAβ+ vs.
PPAAβ−) by hemisphere. Change over 12 months for the four hemisphere/amyloid
subgroups was compared to zero using a t-test from the model. Bonferroni corrected
significance was declared if P < .0125 (0.05/4 for 2 sets of 4 tests). Separate analyses were
done for cortex and PSTCR.
Seven neuropsychological tests were analyzed using a mixed linear model with amyloid
status as the between-subjects factor. To test whether there was significant change over time
within each group, or to compare percent change in test scores between groups, Bonferroni
corrected significance was declared if P <.0071 (0.05/7 for 3 sets of 7 tests).
Univariate linear regression was used to relate baseline cortical volume to 12-month percent
change in cortex or PSTCR volume stratified by hemisphere. This process was repeated for
baseline WAB-AQ (%). For these models, statistical significance was declared if P <.05.
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3.

Results
There were no differences in demographics among the groups (Table 1). The PPA-G
participants were equally distributed between the PPAAβ+ and PPAAβ− groups, whereas the
PPA-L participants tended to be in the PPAAβ+ group.
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Vertex-wise thickness analyses across the cortex were used to identify peak areas of atrophy
at the initial visit of the PPAAβ+ and PPAAβ− groups relative to cognitively healthy controls.
Consistent with previous reports [4,36], both the PPAAβ+ and PPAAβ− groups showed
asymmetric atrophy (LH > RH) most prominently located in the language network at the
initial visit (Fig. 1A). The pattern of atrophy at the initial visit was more pronounced and
widespread in the PPAAβ+ than PPAAβ− group. Compared with controls, peak LH atrophy
on the lateral surface in the PPAAβ+ group included the temporoparietal junction, the inferior
frontal gyrus, superior and caudal middle frontal gyri, fusiform, as well as the superior
middle and inferior temporal gyri including the temporal pole. Peak atrophy in the PPAAβ−
group was primarily in left perisylvian regions including the posterior inferior frontal gyrus,
the superior temporal gyrus, and anterior portions of the middle temporal gyrus and inferior
temporal gyrus.
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There was significant atrophy in the RH of the PPAAβ+ group, which was absent in the
PPAAβ− group. RH atrophy in the PPAAβ+ group was more intense in the temporoparietal
junction, superior temporal gyrus, and middle temporal gyrus.
Because the PPAAβ+ group was nearly twice the size of the PPAAβ−, it is possible that group
differences in atrophy patterns were driven by sample size. To explore this possibility, effect
sizes were examined. Effect size maps largely mirrored atrophy maps, confirming leftward
asymmetry of atrophy in both groups and more extensive atrophy in the PPAAβ+ group (Fig.
1B).
3.2.

Vertex-wise progression of atrophy
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Vertex-based percent change in thickness was examined at each 6-month visit interval (0–6
months and 6–12 months) and also over 12 months for each group (Fig. 2). For each group,
percent change in atrophy was significant over 12 months but not at 6-month intervals.
Twelve-month percent change in atrophy showed leftward asymmetry for both groups.
However, the percent change in atrophy was more extensive in the PPAAβ+ group including
the inferior frontal gyrus, temporoparietal junction, and temporal regions of the LH with RH
change mainly occurring in homologous regions. Percent change in atrophy for the PPAAβ−
group was restricted to the LH, primarily in the middle temporal gyrus.
3.3.

ROI progression of atrophy
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Because the percent change in volume and thickness was negligible at 6-month intervals, the
ROI analysis focused on the 0-to-12-month interval. Percent change in volume for the cortex
and PSTCR ROIs was examined over a 12-month interval to determine if progression of
atrophy (1) was significant for the LH and RH ROIs; (2) was asymmetric; and (3) had
different rates between the PPAAβ+ and PPAAβ− groups.
In the PPAAβ+, percent change in volume over 12 months was significantly different from
zero for the cortex and PSTCR ROIs for both the LH and RH (mean ± SEM for cortex: LH,
3.59 ± 0.53; RH, 2.59 ± 0.54; PSTCR: LH, 4.71 ± 0.73; RH, 3.39 ± 0.66, P values ≤ .0125;
Fig. 3). In the PPAAβ− group, percent change in atrophy was significantly different from
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zero for the LH cortex and PSTCR ROIs but not the RH ROI (mean ± SEM for cortex: LH,
3.08 ± 0.73; RH, 1.11 ± 0.75; PSTCR: LH, 4.03 ± 1.00; RH, 1.53 ± 0.91; Fig. 3).
For both groups, percent change in volume for the cortex ROI over 12 months was greater in
the LH than the RH (P values ≤ .0071; Fig. 3), which is consistent with the vertex-wise
cortical thinning patterns (Fig. 2). Percent change in volume for the PSTCR ROI was
significantly greater for the LH than the RH for the PPAAβ− group (P = .0071) but did not
survive correction for the PPAAβ+ group (P = .04; Fig. 3).
There was no significant difference between the PPAAβ+ and PPAAβ− groups in the percent
change in volume of the cortex or PSTCR ROI by hemisphere over 12 months (Fig. 3).
3.4.

Language performance measures
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Similar to the imaging metrics, decline was small and variable for the language performance
measures at 6-month intervals; therefore, analysis focused on the 0-to-12-month interval
(Table 2). Decline in scores was evident for all but two participants over 12 months, though
there was variability in decline at the individual level by test.
The PPAAβ+ group showed decline on WAB-AQ, Boston Naming Test, and Peabody Picture
Vocabulary Test scores (P values ≤ .0071), whereas the PPAAβ− group did not. There were
no differences in the percent change in decline over 12 months on language performance
measures between the groups. Presence of motor-speech difficulties was similar between the
PPAAβ+ (n = 6) and PPAAβ− (n = 5) groups.
3.5.

Identifying relationships between language performance and atrophy

Author Manuscript

First, we examined whether initial visit severity predicted percent change in atrophy. Initial
severity was queried anatomically by quantifying initial cortical volume while initial WABAQ was used as a general measure of aphasia severity. There were no significant
relationships between initial cortical volume and 12-month percent change in cortex volume
or in PSTCR volume for each hemisphere (P values > .05). Likewise, there were no
significant associations between initial WAB-AQ score and 12-month percent change in
cortex or in PSTCR volume for each hemisphere (P values > .05).
Previous research suggests that neuroimaging measures provide more efficient measures of
change than neuropsychological measures. Effect sizes for percent change measurements
over 12 months were greater for the LH cortex and LH PSTCR volume metrics (effect size
range: 1.43–2.03) than for the WAB-AQ and Boston Naming Test language performance
measures (effect size range: 0.84–1.35) for the PPAAβ+ and PPAAβ− groups.
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4.

Discussion
This study characterized the pace and pattern of atrophy over 1 year in PPA participants with
suspect AD versus non-AD neuropathologic change. Although atrophy was greater in the
LH for both groups, quantitative measurements showed a more widespread pattern of
atrophy in the PPAAβ+ than the PPAAβ− group. These data suggest there may be an
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important interaction between disease-specific proteinopathy and selective vulnerability that
drives distribution and progression of disease.
The more diffuse distribution of atrophy in the PPAAβ+ group may have implications for the
tempo of clinical progression, including the earlier emergence of non-language symptoms
potentially accompanied by declines in activities of daily living. This study did not focus on
precise quantitation of non-language domains; however, activities of daily living
questionnaire and Clinical Dementia Rating tended to be more severe in the PPAAβ+ group
over the 12-month interval.
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Individuals with the PPA-L variant were found in both the PPAAβ+ and PPAAβ− groups,
which is consistent with previous studies showing there is no one-to-one relationship
between clinical phenotype and underlying pathology [4,7,37]. Thus, using PPA-L as a
surrogate for determining underlying pathology remains probabilistic and insufficient at the
individual level.
Longitudinal studies of neuroanatomical change in PPA are relatively uncommon [11–
14,38–42]. Many studies have focused on large-scale measurements of whole-brain volume,
ventricular volume, or cortical volume. The present study used both vertex-based
measurements of cortical thickness as well as targeted (PSTCR) and global (cortex) ROI
measurements. Vertex-wise analyses provide unbiased visual representations of the
anatomical patterns of change across the cortex, which adds to the understanding of the
natural progression of the disease by suspected neuropathology. ROI analyses provide a
common quantitative currency for comparing progression among groups and hold potential
as outcome metrics for clinical trials.
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Effect size results are consistent with previous reports suggesting that structural MR metrics
provide more robust measures of change than cognitive performance measures [11,13,43].
Thus, cortical ROI measures such as the PSTCR may be useful for future clinical trials and
may allow for smaller sample sizes to detect a significant effect. Intriguing summary scores
of language performance are emerging [10] and may be useful to detect change as they are
optimized. Understanding consistency of these measures at the individual level over the
disease course is important before they can be reliably introduced as clinical trial outcome
metrics.
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There was no simple linear relationship between initial volume and percent change over the
relatively short 12-month interval. One potential hypothesis is that individuals with the
smallest baseline volume would show the slowest rate of progression over time, in part,
because there is less brain mass to lose. Our results did not support this conclusion. Percent
change in volume did not show a significant correlation with initial volume or aphasia
severity.
One potential limitation was reliance on florbetapir-PET as the AD biomarker in this study.
Sensitivity and specificity are high for florbetapir (>95%) in individuals who were scanned 1
year before death [44]. PPA participants with elevated amyloid scans could have additional
FTLD or TAR DNA-binding protein 43 pathology. However, data from our previous report
suggest this likelihood is low because only one of 58 consecutive PPA autopsies showed a
Alzheimers Dement. Author manuscript; available in PMC 2020 April 01.
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double diagnosis [5]. Five participants in this study have come to autopsy, and their
florbetapir status was concordant with their neuropathologic diagnosis (i.e., three PPAAβ+
participants had changes consistent with AD and two PPAAβ−, one with FTLD-tau
[progressive supranuclear palsy] and one with FTLD-tau [Pick]). These results reinforce the
possibility of including PPAAβ+ individuals in clinical trials targeting the AD
pathophysiologic process.
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Clinical trials targeting the AD pathophysiological process are underway. Trial-ready
dementia cohorts are emerging from multicenter projects and registries. AD biomarkerpositive PPA patients are appropriate for AD therapeutic trials but are rarely included. The
lack of clarity around appropriate outcome metrics and poor understanding of individual
variability may be influencing their exclusion. Past PPA trials have been handicapped by the
inability to align participants into trials based on likely underlying neuropathology.
Judicious use of in vivo biomarkers provides an opportunity to advocate for the inclusion of
atypical forms of AD into clinical trials.
Preferential neurodegeneration of the LH language network is a common denominator for
both the PPAAβ+ and PPAAβ− groups, even as the disease progresses. These data suggest
disease-specific proteinopathy may be one factor influencing the rate and cortical
distribution of atrophy. However, individual variability was also present. Factors influencing
the rate of atrophy and clinical progression at the individual level remain elusive and require
additional investigation.
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RESEARCH IN CONTEXT

Author Manuscript

1.

Systematic review: The existing literature was reviewed (e.g., PubMed) and
cited. These investigations report variable disease duration for those with
primary progressive aphasia (3–20 years) with few prospective studies
assessing the biological factors influencing rate of decline.

2.

Interpretation: Preferential neurodegeneration of the language network is a
common feature in primary progressive aphasia irrespective of suspected
underlying pathology, even as the disease progresses. However, the nature of
clinical and anatomical progression appears to differ for those with primary
progressive aphasia with suspected Alzheimer versus non-Alzheimer
neuropathology.

3.

Future directions: Although proteinopathy may be one factor influencing the
rate of atrophy and clinical progression, additional factors remain elusive and
require additional investigation. These results reinforce the need for reliable
biomarkers and prospective studies of biological progression which are
necessary for uncovering mechanisms underlying clinical expression,
designing intervention targets and outcomes, and developing care plans for
individuals with aphasic forms of Alzheimer’s disease.
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Fig. 1.
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Characterization of cortical atrophy at initial visit for the PPAAβ+ and PPAAβ− groups. (A)
Vertex-based cortical atrophy patterns by amyloid status at the initial visit. Left: Red/yellow
indicates significant cortical thinning patterns for the PPAAβ+ participants relative to
controls. Right: Red/yellow indicates significant cortical thinning patterns for the PPAAβ−
participants relative to controls. The false discovery rate was set at 0.05 for each
comparison. (B) Cohn’s d effect-size maps by amyloid status at initial visit based on
standard deviation for the PPAAβ+ (left) and PPAAβ− (right) participants. Abbreviations:
PPA, primary progressive aphasia.
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Fig. 2.

Vertex-based percent change in cortical thickness by amyloid status. Red/yellow indicates
significant cortical thinning patterns. The false discovery rate was set at 0.05 for each
comparison. Abbreviation: PPA, primary progressive aphasia.
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Fig. 3.

Percent change over 12 months by hemisphere, amyloid status, and ROI. aPercent change in
volume was significantly different from zero (P <.0125). bPercent change in volume was
significantly greater in the left hemisphere than the right hemisphere (P <.0071). The
middle, upper, and lower horizontal lines in the box plot represent the median, 75th, and
25th percentiles, respectively. The end of the vertical extensions above and below the box
represent the extreme value that is at most 1.5 times the interquartile range above the 75th
percentile or below the 25th percentile. Abbreviations: PPA, primary progressive aphasia;
PSTCR, revised language network ROI defined for the perisylvian cortex; ROI, region of
interest.
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5 (56%)
15.0 (2.2) [12–19]
3.9 (1.3) [2.1–6.0]
6.1 (0.3) [5.2–6.7]

8 (47%)
16.4 (2.4) [12–20]
5.2 (2.8) [1.4–10.9]
6.3 (0.5) [5.5–7.6]

Gender (% M)

Education

Initial visit symptom duration

Months between visits

7 (41%)

Agrammatic

7 (78%)

–

–

16.1 (2.4) [11–20]

14 (56%)

67.8 (5.8) [60–80]

25

NC

NOTE. Numbers are provided as means, (standard deviations), and [Ranges]. Education and symptom duration are provided in years. Months between visits are provided as the average number of months
between initial visit and 6-month visit and 6-month visit and 12-month visit. There were no significant differences in demographics among the groups.

Abbreviations: NC, normal control; PPA, primary progressive aphasia.

10 (59%)

Logopenic

2 (22%)

70.8 (7.2) [61–82]

66.3 (5.8) [58–80]

Age at initial visit

Subtype

9

17

PPAAβ−

N

PPAAβ+
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Demographic and clinical data for the PPAAβ+, PPAAβ−, and control groups
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51.1 (0.07) [13.3–80.0]
12.7 (11.04)

66.2 (0.06) [33.3–100.0]
−1.9 (8.55)

12-month visit

% Change over 12 months

66.3 (0.06) [45.5–90.9]
11.3 (6.63)

59.4 (0.04) [24.2–89.4]
10.1 (4.82)

12-month visit

% Change over 12 months

Alzheimers Dement. Author manuscript; available in PMC 2020 April 01.

‡

3/11/1/2

12-month visit no. 0/0.5/1/2

0/5/7/5
0/2/9/6

Initial visit no. 0/0.5/1/2

12-month visit no. 0/0.5/1/2

CDR-Language

‡

4/11/2/0

Initial visit no. 0/0.5/1/2

CDR-Global

6.6 (2.18)

0/2/4/3

0/1/6/2

4/5/0/0

6/3/0/0

2.0 (3.00)

92.3 (0.04) [83.3–100.0]

†

87.9 (0.03) [55.6–100.0]

12-month visit

% Change over 12 months

94.1 (0.02) [88.9–100.0]

93.8 (0.01) [80.6–100.0]

Initial Visit

PPVT

74.4 (0.05) [50.0–93.9]

66.8 (0.04) [36.4–97.0]

Initial visit

WAB Rep 66

63.0 (0.07) [26.7–100.0]

65.3 (0.05) [33.3–93.3]

13.6 (6.09)

Initial visit

Grammar (NATnc)

24.5 (4.57)

†

69.3 (0.09) [13.3–91.7]

55.1 (0.07) [13.3–98.3]

% Change over 12 months

77.4 (0.07) [25.0–93.3]

69.4 (0.06) [21.7–96.7]

12-month visit

6.7 (3.74)

Initial visit

BNT

11.0 (2.72)

†

78.3 (0.04) [62.8–87.4]

75.4 (0.03) [29.0–94.6]

% Change over 12 months

83.8 (0.03) [71.7–93.6]

84.2 (0.02) [67.8–96.8]

12-month visit

PPAAβ−, (n = 9)

Initial visit

WAB-AQ

PPAAβ+, (n = 17)*

Scores on neuropsychological tests of language and an activities of daily living questionnaire at initial and 12-month visits by group
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‡
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10/7/0

12-month visit no. Mild/Moderate/Severe

9/0/0

9/0/0

Tests were not performed because of zero frequencies and very small numbers in some categories.

‡

†
Indicates significant (P <.0071) decline (relative to zero) within-group as measured by percent change over 12 months.

Data for the BNT were not available for one PPAAβ+ participant. NATnc data were not available for two PPAAβ+ participants.

*

NOTE. The ADLQ is an informant-rated survey of functional impairments. On the ADLQ, functional impairment is rated as none to mild (0%-33%), moderate (34%-66%), or severe (67%-100%). Analysis
focused on the percent change over 12 months.

NOTE. Numbers are provided as means, (standard errors), and [Ranges]. Average percent correct (standard error), [range], and percent change over 12 months are provided by group.

Abbreviations:WAB-AQ, Western Aphasia Battery-Aphasia Quotient; BNT, Boston Naming Test; NATnc, noncanonical items on the Northwestern Anagram Test; WAB Rep 66, items 10–15 on the Western
Aphasia Battery Repetition Subtest; PPVT, a subset of moderately difficult items (items 157–192) from the fourth edition of the Peabody Picture Vocabulary Test; ADLQ, activities of daily living
questionnaire; PPA, primary progressive aphasia.

15/2/0

Initial visit no. Mild/Moderate/Severe

ADLQ
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PPAAβ+, (n = 17)*
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